Grace Therapeutics, Inc.

Contributing Author

Recent Articles by Grace Therapeutics, Inc.

Oct-23	Grace Therapeutics Secures Approximately $4.0 Million through Common Warrant Exercises Following Acceptance of New Drug Application for GTx-104 for formal FDA Review GRCE GlobeNewswire
Sep-22	Grace Therapeutics Pivotal Phase 3 STRIVE-ON Safety Trial Presented at 2025 Neurocritical Care Annual Meeting GRCE GlobeNewswire
Sep-18	Grace Therapeutics Granted Sixth U.S. Patent Covering I.V. Dosing Regimen for GTx-104 GRCE GlobeNewswire
Sep-04	Grace Therapeutics Announces Presentation at The H.C. Wainwright 27th Annual Global Investment Conference GRCE GlobeNewswire
Aug-27	Grace Therapeutics Announces U.S. Food and Drug Administration Acceptance for Review of New Drug Application for GTx-104 GRCE GlobeNewswire
Aug-12	Grace Therapeutics Announces First Quarter 2026 Financial Results, Provides Business Update GRCE GlobeNewswire
Jun-25	Grace Therapeutics Announces Submission of New Drug Application to U.S. Food and Drug Administration for GTx-104 GRCE GlobeNewswire
Jun-23	Grace Therapeutics Announces 2025 Fiscal Year-End Results, Provides Business Update GRCE GlobeNewswire
Jun-13	Grace Therapeutics to Participate in the 2025 BIO International Conference GRCE GlobeNewswire